Clinical & Experimental Immunology

Cover image for Vol. 185 Issue 2

Edited By: M. Peakman

Impact Factor: 3.148

ISI Journal Citation Reports © Ranking: 2015: 63/150 (Immunology)

Online ISSN: 1365-2249

Featured

  • Interleukin-9 and T helper type 9 cells in rheumatic diseases

    Interleukin‐9 and T helper type 9 cells in rheumatic diseases

    T helper type 9 (Th9) cells develop from naive T cells in the presence of transforming growth factor (TGF)-β, interleukin (IL)-4 and thymic stromal lymphopoietin (TSLP). Aberrant Th9 activation may cause the onset and progression of autoimmune and chronic inflammatory diseases such as asthma, rheumatoid and psoriatic arthritis, chronic gut inflammation, kidney diseases, systemic vasculitides and systemic sclerosis. MC = mast cells; Eo = eosinophils; Treg = regulatory T cells.

  • Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

    Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system

    Crystal structure of human dipeptidyl peptidase 4 (DPP4) and bovine adenosine deaminase (ADA) obtained from Protein Data Bank: 1W1I. (a) DPP4 crystal structure associated with bovine ADA at its glycosylation-rich region of the propeller domain. (b) Top view of propeller domain, showing ADA binding site at bladea 4 and 5 as well as ADA interactions with carbohydrates of N229. (c) Caveolin-1 binding site at aa 201–210 and Ser630.

  • MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset

    MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset

    Structure of the major histocompatibility complex class I chain-related gene A (MICA). (a) View of a ribbon representation of the crystal structure of MICA. Only the extracellular region is shown, which consists of two structural domains: α1α2 platform and α3. The α1α2 platform consists of four α-helices arranged on eight anti-parallel β-sheets. The α3 domain, a C-type immunoglobulin-like domain, is not in contact with the platform. Image from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (www.rcsb.org) (ID 1B3J) . (b) Diagram of the transmembrane region and the cytoplasmic tail of MICA. Full-length MICA molecules (coded by MICA*A4, MICA*5, MICA*A6 and MICA*A9) are transmembrane (TM) proteins, whereas MICA*A5.1 attaches to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor and has no cytoplasmic tail. The sequence of amino acids of the TM region is shown in the lower box. The alleles differ in the number of trinucleotide GCT repetitions that code alanine (underlined); the frameshift in MICA*A5.1, due to a guanine insertion after the second GCT triplet, leads to a premature stop codon (black triangle).

  • From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals

    From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals

    Methods for the detection of neutralizing antibodies (NAb). A bioassay (a,b) models the drug's functional activity in an in-vitro test method. Cells expressing drug target ‘T’ are incubated with drug ‘D’. When the drug binds the cell-surface target it elicits a cellular response (such as cell proliferation, cell death, cytokine release or cyclic adenosine monophosphate (cAMP) production) which is measured by a subsequent method. (a) Non-NAb (Y-shaped grey symbol) engage drug but do not inhibit the binding of drug with its target, hence the cellular response is not inhibited. (b) NAb (Y-shaped red symbol) bind the drug's active site, blocking the interaction of drug and cell-surface target, thereby inhibiting the cellular response. The principle of a NAb immunoassay is shown in panels (c) and (d). Labelled drug-target ‘T’ is captured by platebound reagent drug ‘D’, generating an assay signal. (c) Non-NAb (Y-shaped grey symbol) are captured by platebound reagent drug, but the anti-drug antibodies (ADA) binding site distal from the drug's active site allows engagement of labelled target and generation of an immunoassay signal. (d) NAb (Y-shaped red symbol) bind platebound reagent drug and inhibit binding of labelled drug-target, reducing assay signal.

  • The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor

    The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor

    Foot blood flow monitored in vivo by laser Doppler perfusion imaging (LDPI) in untreated control arthritic, BoxA-treated and high-mobility group box 1 (HMGB1)-treated mice. Representative evaluation of an HMGB1-treated mice 7 (left) and 21 days (right) after arthritis induction. In colour-coded images, red indicates normal perfusion while yellow indicates reduced perfusion and blue indicates a marked reduction in blood flow in the hindlimb. The results are expressed as the ratio between the perfusion of the sum of the four limbs with that measured before the induction of arthritis. The blood flow of the arthritic joint is expressed as the ratio between perfusion of day 0 versus days 7, 14 and 21. *P < 0·05 versus control collagen antibody-induced arthritis (CAIA) mice. The number of vessels per field, obtained by evaluation of the CD31-positive cells, was increased significantly in HMGB1-treated mice with respect to control CAIA mice; n = 5 mice per group.

  • Collagen-induced arthritis increases inducible nitric oxide synthase not only in aorta but also in the cardiac and renal microcirculation of mice

    Collagen-induced arthritis increases inducible nitric oxide synthase not only in aorta but also in the cardiac and renal microcirculation of mice

    Increased inducible nitric oxide synthase (iNOS) immunolabelling in arthritic kidney medulla. (b) The collagen-induced arthritis (CIA) group presents increased iNOS immunolabelling in the interstitium (red arrows), compared to the control group (a). Counterstain: haematoxylin. Bars: 20 μm. (c) Densitometric analysis (arbitrary units, a.u.). Bars express mean ± standard deviation (n = 6; one-way analysis of variance (anova) followed by Bonferroni's post-test; *P < 0·01).

  • Immunology of membranous nephropathy: from animal models to humans

    Immunology of membranous nephropathy: from animal models to humans

    Granular subepithelial deposits of immunoglobulin (Ig)G in a case of idiopathic membranous nephropathy (original magnification ×400).

  • CD4 T cell differentiation in type 1 diabetes

    CD4 T cell differentiation in type 1 diabetes

    Potential effects of interleukin (IL)-21 on immune cells in type 1 diabetes. IL-21 is a highly pleiotropic cytokine and could potentially act on several different cell types in the context of type 1 diabetes development (see text for references).

  • Interleukin‐9 and T helper type 9 cells in rheumatic diseases
  • Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system
  • MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset
  • From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals
  • The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor
  • Collagen-induced arthritis increases inducible nitric oxide synthase not only in aorta but also in the cardiac and renal microcirculation of mice
  • Immunology of membranous nephropathy: from animal models to humans
  • CD4 T cell differentiation in type 1 diabetes

Recently Published Issues

See all

Published Articles

Accepted Articles |  Most Accessed 2015

MORE

Download the App

Now available on Android and iOS

CEI Andriod App

CEI iOS App

Download the CEI Android App from the Google Play Store

Download the CEI iOS App from the Apple Store

More information on accessing the Clinical & Experimental Immunology App.


International Congress of Immunology 2016 – Melbourne Australia

The 6th International Congress of Immunology (ICI) will take place the 21-26 August 2016 in Melbourne, Australia.

More information about registration, speakers and other important dates.

About Clinical & Experimental Immunology

  • Submission to First Decision: 14 days
  • 2015 Impact Factor: 3.148
  • All Clinical & Experimental Immunology review articles are free-to-access from point of publication, and all journal content is free-to-access after a period of 12 months

British Society for Immunology News

BSI website

Bite-Sized Immunology is a developing online resource, with downloadable content, designed to form a comprehensive guide to the immune system.

Bite-Sized Immunology


Visit the British Society for Immunology on Social Media:

  • BSI Twitter
  • BSI Facebook
  • BSI YouTube Channel
  • BSI Instagram
  • BSI Linked In

SEARCH

SEARCH BY CITATION